In what could be a miracle improving and saving thousands of lives across the globe, Russia's mRNA-based vaccine Enteromix has displayed 100% efficacy and safety in clinical trials . This could be a hope against fighting aggressive cancers and preventing them.
"The Russian Enteromix cancer vaccine is now ready for clinical use, the Federal Medical and Biological Agency (FMBA) has announced. FMBD head Veronica Skvortsova said the mRNA-based vaccine had successfully passed preclinical trials, demonstrating its safety and high effectiveness. The vaccine showed significant results in shrinking tumors and slowing their growth, and has also been found safe for repeated use. The vaccine will be customized for each patient, tailored to their individual RNA, Skvortsova said. She added that the first form of the vaccine will be used to treat colorectal cancer, while another version is in development for glioblastoma — a brain cancer — and specific types of melanoma, a skin cancer," Sputnik, a global wire and digital news service has posted on X.
Enteromix was developed using cutting-edge technology, similar to the one used in COVID-19 vaccines. It works by training the immune system to recognize and eliminate cancer cells. Additionally, it is personalized for every individual patient.
Interestingly, unlike chemotherapy or radiation, there were no serious side effects of the vaccine and patients tolerated it well.
Earlier, it was revealed that Russia had begun clinical trials of the new EnteroMix oncolytic vaccine with 48 participating volunteers. The drug was developed by the country's Ministry of Health 's National Medical Research Radiology Centre in collaboration with the Engelhardt Institute of Molecular Biology (EIMB) of the Russian Academy of Science (RAS).
The start of the clinical trial was announced at the St. Petersburg International Economic Forum (SPIEF 2025), held from June 18 to 21 in northern Russia. The event, organized by the Roscongress agency under the Russian President’s office, showcased Russia’s progress in medical research and biotechnology.
As per a report in MedPath, Enteromix makes use of four harmless viruses to attack and destroy cancerous tumours while also boosting the immune system to fight the disease. After going through several years of testing, it has shown effectiveness in slowing down growth and in some cases completely destroying the cancer.
With the trials out of the way, the only remaining step is regulatory clearance. If approved, Enteromix could become the first personalized mRNA cancer vaccine available to the public.
"The Russian Enteromix cancer vaccine is now ready for clinical use, the Federal Medical and Biological Agency (FMBA) has announced. FMBD head Veronica Skvortsova said the mRNA-based vaccine had successfully passed preclinical trials, demonstrating its safety and high effectiveness. The vaccine showed significant results in shrinking tumors and slowing their growth, and has also been found safe for repeated use. The vaccine will be customized for each patient, tailored to their individual RNA, Skvortsova said. She added that the first form of the vaccine will be used to treat colorectal cancer, while another version is in development for glioblastoma — a brain cancer — and specific types of melanoma, a skin cancer," Sputnik, a global wire and digital news service has posted on X.
🚨🇷🇺💉Russian scientists unveil mRNA cancer vaccine ready for use
— Sputnik (@SputnikInt) September 6, 2025
The Russian Enteromix cancer vaccine is now ready for clinical use, the Federal Medical and Biological Agency (FMBA) has announced.
FMBD head Veronica Skvortsova said the mRNA-based vaccine had successfully… pic.twitter.com/Q91FTK4obk
Enteromix was developed using cutting-edge technology, similar to the one used in COVID-19 vaccines. It works by training the immune system to recognize and eliminate cancer cells. Additionally, it is personalized for every individual patient.
Interestingly, unlike chemotherapy or radiation, there were no serious side effects of the vaccine and patients tolerated it well.
Earlier, it was revealed that Russia had begun clinical trials of the new EnteroMix oncolytic vaccine with 48 participating volunteers. The drug was developed by the country's Ministry of Health 's National Medical Research Radiology Centre in collaboration with the Engelhardt Institute of Molecular Biology (EIMB) of the Russian Academy of Science (RAS).
The start of the clinical trial was announced at the St. Petersburg International Economic Forum (SPIEF 2025), held from June 18 to 21 in northern Russia. The event, organized by the Roscongress agency under the Russian President’s office, showcased Russia’s progress in medical research and biotechnology.
As per a report in MedPath, Enteromix makes use of four harmless viruses to attack and destroy cancerous tumours while also boosting the immune system to fight the disease. After going through several years of testing, it has shown effectiveness in slowing down growth and in some cases completely destroying the cancer.
With the trials out of the way, the only remaining step is regulatory clearance. If approved, Enteromix could become the first personalized mRNA cancer vaccine available to the public.
You may also like
Alabama tragedy: Auburn vet professor killed while walking dog; suspect charged with capital murder
Assam CM Himanta Biswa Sarma Urges Bihu Committees To Dedicate One Evening To Bhupen Hazarika's Legacy
On 75th birthday, PM Modi to lay foundation stone of 'PM Mitra' park in MP
Himachal becoming fully literate a testimony of joint efforts of govt, society: Dharmendra Pradhan
Master plan to be prepared for development of Telangana's two major temples
